To investigate the safety and efficacy of QMF149 , a once-daily , fixed-dose combination of the long-acting 2-agonist ( LABA ) indacaterol maleate and inhaled corticosteroid ( ICS ) mometasone furoate ( MF ) for the treatment of persistent asthma .